The following day, Jefferies' Andrew Andersen raised his existing price target on the shares. He now believes they are worth $37 apiece, quite some distance north of his previous $30 estimation. That was the good news for Lemonade; the bad is that Andersen left his underperform (sell) rating unchanged. According to reports, the analyst's bump was due in no small to the company's higher premium retention; this should spur revenue growth for the company. On the down side, Andersen expressed concern that Lemon ...